uniQure (NASDAQ:QURE) Price Target Lowered to $9.00 at The Goldman Sachs Group

uniQure (NASDAQ:QURE) had its price objective reduced by equities researchers at The Goldman Sachs Group from $37.00 to $9.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has a “neutral” rating on the biotechnology company’s stock. The Goldman Sachs Group’s price target would suggest a potential upside of 0.83% from the company’s previous close.

Several other equities research analysts also recently issued reports on the company. Royal Bank Of Canada downgraded uniQure from a “moderate buy” rating to a “hold” rating and set a $11.00 price objective for the company. in a research note on Monday. Barclays began coverage on uniQure in a report on Tuesday, January 27th. They issued an “equal weight” rating and a $31.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of uniQure in a research report on Wednesday, January 21st. William Blair restated a “market perform” rating on shares of uniQure in a report on Tuesday, November 11th. Finally, Wall Street Zen lowered shares of uniQure from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. Seven analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, uniQure has a consensus rating of “Hold” and a consensus target price of $34.33.

uniQure Trading Down 15.0%

Shares of NASDAQ QURE traded down $1.57 during mid-day trading on Tuesday, hitting $8.93. 2,917,063 shares of the company traded hands, compared to its average volume of 2,757,464. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.23. uniQure has a 1 year low of $7.76 and a 1 year high of $71.50. The stock has a market capitalization of $556.00 million, a price-to-earnings ratio of -2.05 and a beta of 0.73. The business has a 50 day moving average of $23.17 and a two-hundred day moving average of $29.77.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.37. The firm had revenue of $5.57 million during the quarter, compared to analyst estimates of $4.84 million. uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%. On average, sell-side analysts anticipate that uniQure will post -3.75 earnings per share for the current fiscal year.

Insider Buying and Selling at uniQure

In other uniQure news, Director Jack Kaye sold 6,390 shares of the business’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $27.28, for a total value of $174,319.20. Following the completion of the sale, the director owned 20,439 shares of the company’s stock, valued at $557,575.92. The trade was a 23.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Christian Klemt sold 6,217 shares of the stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $23.86, for a total value of $148,337.62. Following the transaction, the chief financial officer directly owned 211,513 shares in the company, valued at approximately $5,046,700.18. This represents a 2.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 50,598 shares of company stock valued at $1,248,588. Company insiders own 4.79% of the company’s stock.

Institutional Investors Weigh In On uniQure

A number of large investors have recently added to or reduced their stakes in QURE. Private Trust Co. NA acquired a new position in uniQure during the third quarter valued at approximately $28,000. Torren Management LLC bought a new stake in shares of uniQure during the 4th quarter worth $28,000. Jones Financial Companies Lllp grew its stake in uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 509 shares during the last quarter. IFP Advisors Inc acquired a new position in uniQure in the 4th quarter valued at $48,000. Finally, Smartleaf Asset Management LLC bought a new position in uniQure in the 4th quarter worth $48,000. Institutional investors own 78.83% of the company’s stock.

Key Stories Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Q4 earnings beat expectations — uniQure reported a smaller-than-expected loss and revenue slightly above consensus, which is a constructive near-term financial data point. Earnings Call Transcript
• Positive Sentiment: Some analysts still see upside — Chardan kept a buy rating while lowering its target to $16, signaling that at least one shop views the shares as a recovery/re‑risk opportunity. Chardan coverage
• Neutral Sentiment: Company will engage with FDA on next steps — uniQure said it’s evaluating Phase 3 development options and plans a follow-up Type B meeting with the FDA in Q2, which keeps the program alive but adds time and cost. Company Update
• Neutral Sentiment: Corporate governance change flagged — uniQure disclosed it will fall under the Dutch “large company” regime in 2026, a governance shift investors should monitor for board/ shareholder dynamics. Governance Risk
• Negative Sentiment: FDA rejected uniQure’s early‑approval pathway and requested a new randomized (sham‑controlled) Phase 3 study for AMT‑130 — that regulatory demand is the main cause of today’s share decline because it materially lengthens development timelines, increases costs, and raises trial risk. FDA story
• Negative Sentiment: Multiple analyst downgrades and big target cuts — firms including Cantor Fitzgerald, RBC, Mizuho and Wells Fargo cut targets and/or ratings this morning, signaling reduced near‑term conviction and pressuring sentiment. Analyst actions
• Negative Sentiment: Class‑action litigation piling up — several law firms have filed or solicited claims related to late‑2025 disclosures, adding legal overhang and potential monetary exposure. Class action notice

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.